MA31858B1 - N-phenyl-bipyrrolidine-carboxamides substitues et utilisation therapeutique de ceux-ci - Google Patents

N-phenyl-bipyrrolidine-carboxamides substitues et utilisation therapeutique de ceux-ci

Info

Publication number
MA31858B1
MA31858B1 MA32850A MA32850A MA31858B1 MA 31858 B1 MA31858 B1 MA 31858B1 MA 32850 A MA32850 A MA 32850A MA 32850 A MA32850 A MA 32850A MA 31858 B1 MA31858 B1 MA 31858B1
Authority
MA
Morocco
Prior art keywords
phenyl
substituted
bipyrrolidine
carboxamides
therapeutic use
Prior art date
Application number
MA32850A
Other languages
English (en)
Inventor
Werngard Czechtizky
Zhongli Gao
William J Hurst
Lothar Schwink
Siegfried Stengelin
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA31858B1 publication Critical patent/MA31858B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE ET REVENDIQUE UNE SÉRIE DE CARBOXAMIDES DE N-PHÉNYL-BIPYRROLIDINE SUBSTITUÉS DE FORMULE (I) TELLE QUE DÉCRITE DANS LE PRÉSENT DOCUMENT. PLUS PARTICULIÈREMENT, LES COMPOSÉS DE CETTE INVENTION SONT DES MODULATEURS DES RÉCEPTEURS H3 ET SONT, PAR CONSÉQUENT, UTILES EN TANT QU'AGENTS PHARMACEUTIQUES, EN PARTICULIER DANS LE TRAITEMENT ET/OU LA PRÉVENTION D'UNE VARIÉTÉ DE MALADIES MODULÉES PAR LES RÉCEPTEURS H3, Y COMPRIS LES MALADIES ASSOCIÉES AU SYSTÈME NERVEUX CENTRAL. DE PLUS, CETTE INVENTION CONCERNE ÉGALEMENT DES PROCÉDÉS DE PRÉPARATION DE CARBOXAMIDES DE N-PHÉNYL-BIPYRROLIDINE SUBSTITUÉS ET DE LEURS COMPOSÉS INTERMÉDIAIRES.
MA32850A 2007-10-17 2010-05-17 N-phenyl-bipyrrolidine-carboxamides substitues et utilisation therapeutique de ceux-ci MA31858B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98059907P 2007-10-17 2007-10-17

Publications (1)

Publication Number Publication Date
MA31858B1 true MA31858B1 (fr) 2010-11-01

Family

ID=40247942

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32850A MA31858B1 (fr) 2007-10-17 2010-05-17 N-phenyl-bipyrrolidine-carboxamides substitues et utilisation therapeutique de ceux-ci

Country Status (25)

Country Link
US (2) US8088808B2 (fr)
EP (1) EP2212283B1 (fr)
JP (1) JP5377503B2 (fr)
KR (1) KR20100072077A (fr)
CN (1) CN101903340B (fr)
AT (1) ATE525351T1 (fr)
AU (1) AU2008312635B2 (fr)
BR (1) BRPI0818581A2 (fr)
CA (1) CA2702467C (fr)
CY (1) CY1112083T1 (fr)
DK (1) DK2212283T3 (fr)
ES (1) ES2372332T3 (fr)
HR (1) HRP20110762T1 (fr)
IL (1) IL205001A (fr)
MA (1) MA31858B1 (fr)
MX (1) MX2010003949A (fr)
MY (1) MY151348A (fr)
NZ (1) NZ584690A (fr)
PL (1) PL2212283T3 (fr)
PT (1) PT2212283E (fr)
RS (1) RS52235B (fr)
RU (1) RU2477720C2 (fr)
SI (1) SI2212283T1 (fr)
WO (1) WO2009052062A1 (fr)
ZA (1) ZA201002115B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2702834C (fr) 2007-10-17 2013-01-15 Sanofi-Aventis Amides de n-phenyl-pyrrolidinylmethylpyrrolidine substitues et leur utilisation therapeutique comme modulateurs du recepteur h3 de l'histamine
CN101903341B (zh) 2007-10-17 2012-10-03 赛诺菲-安万特 取代的n-苯基-联吡咯烷脲及其治疗用途
MY151348A (en) * 2007-10-17 2014-05-15 Sanofi Aventis Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
AU2008312638B2 (en) * 2007-10-17 2013-05-16 Sanofi-Aventis Substituted N-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
AR074467A1 (es) 2008-12-05 2011-01-19 Sanofi Aventis Tetrahidropiran espiro pirrolidinonas y piperidinonas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento y/o prevencion de enfermedades del snc ,tales como alzheimer y parkinson, entre otras.
AR074466A1 (es) 2008-12-05 2011-01-19 Sanofi Aventis Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.
SA110310332B1 (ar) * 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
EP2569303A1 (fr) 2010-05-11 2013-03-20 Sanofi Dérivés n-alkyl et n-acyl tétrahydro-isoquinoline substitués, procédé de préparation et application thérapeutiques associés
JP2013529198A (ja) 2010-05-11 2013-07-18 サノフイ 置換されたｎ−ヘテロシクロアルキルビピロリジニルフェニルアミド誘導体、その製造及び治療上の使用
TW201202251A (en) * 2010-05-11 2012-01-16 Sanofi Aventis Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof
TW201206939A (en) 2010-05-11 2012-02-16 Sanofi Aventis Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof
EP2569296A1 (fr) * 2010-05-11 2013-03-20 Sanofi Bipyrrolidines n-phényl spirolactame substituées, procédé de préparation et usage thérapeutique associés
AR081383A1 (es) 2010-05-11 2012-08-29 Sanofi Aventis N-heteroaril bipirrolidin carboxamidas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de enfermedades del sistema nervioso central.
JP5784110B2 (ja) 2010-05-11 2015-09-24 サノフイ 置換されたｎ−ヘテロアリールテトラヒドロ−イソキノリン誘導体、その製造及び治療上の使用
MX2012015102A (es) * 2010-07-06 2013-05-01 Astrazeneca Ab Agentes terapeuticos 976.
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
JP2013232564A (ja) * 2012-04-27 2013-11-14 National Institute Of Advanced Industrial & Technology 半導体装置および半導体装置の製造方法
CN108250128A (zh) * 2012-09-27 2018-07-06 江苏先声药业有限公司 作为钾通道调节剂的化合物
EP2943196A1 (fr) 2013-01-10 2015-11-18 Grünenthal GmbH Carboxamides i à base de pyrazolyl à utiliser en tant qu'inhibiteurs du canal crac
EP2943197A1 (fr) 2013-01-10 2015-11-18 Grünenthal GmbH Carboxamides ii à base de pyrazolyle servant d'inhibiteurs de crac
EP3366683A1 (fr) 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Amides, acetamides et ureas cycliques pour ouvris les voies de calcium

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
EP1556046A1 (fr) * 2002-10-23 2005-07-27 Janssen Pharmaceutica N.V. Phenylpiperidines et phenylpyrrolidines utilisees comme modulateurs du recepteur h3 de l'histamine
US7223788B2 (en) * 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
DE10306250A1 (de) * 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2335305T3 (es) 2005-03-17 2010-03-24 Eli Lilly And Company Derivados de pirrolidina como antagonistas del receptor h3 de histamina.
WO2006107661A1 (fr) * 2005-04-01 2006-10-12 Eli Lilly And Company Agents agissant sur le recepteur h3 de l'histamine, leur preparation et leurs utilisations therapeutiques
MX2007016216A (es) * 2005-07-01 2008-03-11 Lilly Co Eli Agenes del receptor de histamina h3, preparacion y usos terapeuticos.
AU2006308167A1 (en) * 2005-10-27 2007-05-03 Ucb Pharma, S.A. Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses
AU2007214709A1 (en) * 2006-02-15 2007-08-23 Sanofi-Aventis Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
CA2702834C (fr) 2007-10-17 2013-01-15 Sanofi-Aventis Amides de n-phenyl-pyrrolidinylmethylpyrrolidine substitues et leur utilisation therapeutique comme modulateurs du recepteur h3 de l'histamine
CN101903341B (zh) 2007-10-17 2012-10-03 赛诺菲-安万特 取代的n-苯基-联吡咯烷脲及其治疗用途
AU2008312638B2 (en) * 2007-10-17 2013-05-16 Sanofi-Aventis Substituted N-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
MY151348A (en) * 2007-10-17 2014-05-15 Sanofi Aventis Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof

Also Published As

Publication number Publication date
RU2010119528A (ru) 2011-11-27
WO2009052062A1 (fr) 2009-04-23
ES2372332T3 (es) 2012-01-18
AU2008312635A1 (en) 2009-04-23
AU2008312635B2 (en) 2013-05-16
ATE525351T1 (de) 2011-10-15
HRP20110762T1 (hr) 2011-11-30
JP5377503B2 (ja) 2013-12-25
NZ584690A (en) 2011-09-30
US20120065234A1 (en) 2012-03-15
RS52235B (sr) 2012-10-31
PL2212283T3 (pl) 2012-01-31
CY1112083T1 (el) 2015-11-04
US8088808B2 (en) 2012-01-03
MX2010003949A (es) 2010-04-30
IL205001A (en) 2014-06-30
CN101903340A (zh) 2010-12-01
IL205001A0 (en) 2010-11-30
CN101903340B (zh) 2013-03-27
CA2702467A1 (fr) 2009-04-23
DK2212283T3 (da) 2011-12-19
HK1146053A1 (en) 2011-05-13
CA2702467C (fr) 2012-11-27
PT2212283E (pt) 2011-11-03
EP2212283B1 (fr) 2011-09-21
SI2212283T1 (sl) 2011-12-30
ZA201002115B (en) 2010-12-29
US8252824B2 (en) 2012-08-28
RU2477720C2 (ru) 2013-03-20
US20100173949A1 (en) 2010-07-08
KR20100072077A (ko) 2010-06-29
BRPI0818581A2 (pt) 2015-07-21
EP2212283A1 (fr) 2010-08-04
JP2011500693A (ja) 2011-01-06
MY151348A (en) 2014-05-15

Similar Documents

Publication Publication Date Title
DK2212283T3 (da) Substituerede N-phenylbipyrrolidincarboxamider og terapeutisk anvendelse deraf
MA31855B1 (fr) Carboxamides de n-phényl-bipyrrolidine substitués et leur utilisation thérapeutique
MA31889B1 (fr) N-phenyl -bipyrrolidine-urees substituees et utilisation therapeutique de celles-ci
MX2010004003A (es) N-fenil-pirrolidinilmetlipirrolidin amidas sustituidas y uso terapeutico de las mismas.
TN2011000233A1 (en) Substituted piperidine spiro pyrrolidinone and piperidinones used as h3 modulators
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
NO20081975L (no) Diarylamin-inneholdende forbindelser og sammensetninger, og deres anvendelse som modulatorer av C-kit-reseptorer
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
UA104880C2 (uk) Заміщені тетрагідропіранспіропіролідинон і тетрагідропіранспіропіперидинон, спосіб їх одержання й застосування в лікувальних цілях
ATE466854T1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren
MX2008002158A (es) Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6.
ATE479691T1 (de) 4,5,6,7-tetrahydrothienoä2,3-cüpyridine als h3- modulatoren
ATE502947T1 (de) 4,5,6,7-tetrahydrothienoä3,2-cüpyridinderivate als h3-modulatoren
TH149042A (th) การเตรียมเตตระไฮโดรไพแรน สไปโร ไพโรลิดิโนนที่ถูกแทนที่ และพิเพอริดิโนน และการใช้ประโยชน์ในการรักษาของมัน